Market Place
Sourcing Support
Johnson & Johnson CEO warns US tariffs may disrupt drug supply
16 Apr 2025 //
REUTERS
Johnson & Johnson Reports Q1 2025 Results
15 Apr 2025 //
BUSINESSWIRE
Johnson & Johnson Raises Quarterly Dividend by 4.8% for 63rd Year
15 Apr 2025 //
BUSINESSWIRE
Icotrokinra: 75% of adolescents with psoriasis achieve clear skin
10 Apr 2025 //
PR NEWSWIRE
J&J showcases long-term data on nipocalimab in Myasthenia Gravis
08 Apr 2025 //
PR NEWSWIRE
EU Commission OKs Rybrevant with Enhanze for EGFR Lung Cancer
07 Apr 2025 //
PR NEWSWIRE
Tremfya reduces signs, symptoms, and damage in psoriatic arthritis
04 Apr 2025 //
PR NEWSWIRE
J & J Announces Expected Closing Date for Intra-Cellular Acquisition
01 Apr 2025 //
BUSINESSWIRE
US judge rejects J&J`s $10 billion baby powder settlement
01 Apr 2025 //
REUTERS
Johnson & Johnson to Defeat Talc Claims in Tort System
31 Mar 2025 //
BUSINESSWIRE
J&J unit ordered to pay $1.64 B in HIV drug marketing case
29 Mar 2025 //
REUTERS
Tremfya® gets CHMP approval for Crohn’s Disease treatment
28 Mar 2025 //
GLOBENEWSWIRE
Rybrevanta plus Lazcluze outperforms osimertinib in lung cancer
27 Mar 2025 //
PR NEWSWIRE
RYBREVANT plus LAZCLUZE® demonstrates overall survival benefit
26 Mar 2025 //
GLOBENEWSWIRE
Nipocalimab data at AAN 2025 show positive Phase 3 results
26 Mar 2025 //
PR NEWSWIRE
J&J touts $55B in planned US investments over 4 years
22 Mar 2025 //
BUSINESSWIRE
J&J`s Tremfya picks up key FDA nod in Crohn`s disease
21 Mar 2025 //
FIERCE PHARMA
Rybrevant, Lazcluze Show Strong Data In 1L EGFR Lung Cancer
20 Mar 2025 //
PR NEWSWIRE
Nipocalimab granted FDA Breakthrough and Fast Track designations
18 Mar 2025 //
PR NEWSWIRE
J&J, Legend to invest $150M in Belgium cell therapy facility
13 Mar 2025 //
FIERCE PHARMA
Lilly, J&J boosted spending on security after UnitedHealth shooting
13 Mar 2025 //
REUTERS
Steqeyma, A Stelara Biosimilar, Now Available In The US
12 Mar 2025 //
PR NEWSWIRE
Lilly, J&J Boosted Executive Security Spend After UNH Shooting
12 Mar 2025 //
REUTERS
J&J to stop studies of depression drug due to low effectiveness
08 Mar 2025 //
REUTERS
Johnson & Johnson Investor Call on First-Quarter Results
05 Mar 2025 //
BUSINESSWIRE
Johnson & Johnson Names Darren Snellgrove VP, Investor Relations
04 Mar 2025 //
BUSINESSWIRE
J&J’s DARZALEX Gets Positive CHMP Nod For Newly Diagnosed MM
28 Feb 2025 //
GLOBENEWSWIRE
TREMFYA Gets Positive CHMP Opinion For Ulcerative Colitis
28 Feb 2025 //
GLOBENEWSWIRE
J&J sues Samsung Bioepis over contract breach for Stelara
27 Feb 2025 //
REUTERS
Yaqrit Strengthens Board & Management For Liver Disease Trials
21 Feb 2025 //
GLOBENEWSWIRE
Intra-Cellular Therapies Reports Q4 & Full-Year 2024 Results
21 Feb 2025 //
GLOBENEWSWIRE
J&J begins crucial battle over $10 billion baby powder settlement
19 Feb 2025 //
REUTERS
Perceive Pharma Attracts $15M Series A Financing
18 Feb 2025 //
PR NEWSWIRE
J&J resumes rollout of Varipulse heart device after investigation
15 Feb 2025 //
REUTERS
Sanofi takes $250M hit after J&J E. coli vaccine fails in ph. 3
14 Feb 2025 //
PRESS RELEASE
DIA 2025 Meeting Highlights Need For Neutral Biomedical Collab
12 Feb 2025 //
BUSINESSWIRE
J&J Launches TECNIS PureSee Intraocular Lens In India
11 Feb 2025 //
INDPHARMAPOST
J&J to Participate in Annual TD Cowen Healthcare Conference
03 Feb 2025 //
BUSINESSWIRE
CHMP Recommends Subcutaneous Rybrevant for EGFR-mutated NSCLC
03 Feb 2025 //
GLOBENEWSWIRE
US government seek over $1 B from J&J for cancer treatment costs
01 Feb 2025 //
REUTERS
J&J upholds sales growth confidence as Stelara biosims file in
24 Jan 2025 //
FIERCE PHARMA
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
22 Jan 2025 //
BUSINESSWIRE
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
22 Jan 2025 //
GLOBENEWSWIRE
FDA approves J&J`s ketamine-derived depression treatment
22 Jan 2025 //
PRESS RELEASE
Sumitomo to market Johnson & Johnson`s schizophrenia drug in Japan
21 Jan 2025 //
BIOSPECTRUM
New Bladder Cancer Treatment Enters FDA Review Process
15 Jan 2025 //
PR NEWSWIRE
J&J doubles down on neurological drugs with $14.6 billion deal
14 Jan 2025 //
REUTERS
ORIC Signs Supply Deal To Study ORIC-114 With Amivantamab In NSCLC
13 Jan 2025 //
GLOBENEWSWIRE
J&J explores bid for Intra-Cellular Therapies, reports
13 Jan 2025 //
REUTERS
Nipocalimab granted FDA Review for Myasthenia gravis
10 Jan 2025 //
PR NEWSWIRE
J&J pauses Varipulse US debut following 4 reports of strokes
08 Jan 2025 //
FIERCE BIOTECH
J & J Posdinemab and Tau Active Receive FDA Fast Track Designations
08 Jan 2025 //
PR NEWSWIRE
J&J`s combo extend patient` lives in study with AstraZeneca`s drug
08 Jan 2025 //
FIERCE PHARMA
Johnson & Johnson Announces Quarterly Dividend for Q1 2025
02 Jan 2025 //
BUSINESSWIRE
EU clears J&J`s Rybrevant,Lazcluze duo for first-line lung cancer
31 Dec 2024 //
PRESS RELEASE
Kaken, J&J ink potential $1.2B-plus STAT6 deal
28 Dec 2024 //
PRESS RELEASE
Johnson & Johnson Seeks EMA Approval for IMBRUVICA® in MCL
18 Dec 2024 //
GLOBENEWSWIRE
FDA declines to approve injection form of J&J`s lung cancer drug
17 Dec 2024 //
REUTERS
Johnson & Johnson To Join 43rd J.P. Morgan Healthcare Conference
12 Dec 2024 //
BUSINESSWIRE
ICER calls out drugmakers over `unsupported` price hikes
12 Dec 2024 //
REUTERS
